Autoimmune disease drug discovery is a significant area of interest for our scientists. We have developed in vivo models of rheumatoid arthritis, psoriasis and inflammatory bowel disease, among others in this area. These models are combined with the appropriate biomarkers, including flow cytometry and histologic analysis, for a study design tailored to meet the strategic goals of our partners’ programs.

Inflammatory diseases include a range of disorders and our portfolio of in vivo inflammatory disease animal models reflects the diversity of the pathologies covered in this area. Delayed-type hypersensitivity models (type IV hypersensitivity), passive cutaneous anaphylaxis (PCA) hypersensitivity (type I hypersensitivity) models, as well as in vivo models of edema, inflammatory cell recruitment and immune function have been validated to support inflammatory disease drug discovery research.

Our scientists can help elucidate the complex chemical and biological processes of inflammation; the integrated teams at Discovery from Charles River have successfully delivered over two dozen development candidates across multiple target classes with inflammation and immunology indications. Their expertise gives our partners access to an unparalleled scope of therapeutic area-focused knowledge.